If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ™ (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
VIDEO: What were the results of the phase 2 clinical trial of mirikizumab for the treatment of Crohn's disease in adults?
Patients with moderate-to-severe Crohn’s disease who received mirikizumab achieved endoscopic response at week 12, and the efficacy of mirikizumab was sustained to week 52. Incidences of adverse events were similar for mirikizumab and placebo.
Date of Last Review: February 23, 2022
Document Number: VV-MED-119568